The presence of an operational classification of drug interactions (ORCA) class 3 or 4 drug-drug interactions (DDIs) did not increase the risk for colchicine-related gastrointestinal adverse events or ...
NEW YORK — New insights into colchicine's disruption of the pathway that contributes to arterial inflammation and new clinical studies of the drug could pave the way toward greater use of the ...
An anti-inflammatory drug that has been around for over 2,000 years might help delay a very modern problem: hip and knee replacements. That's the suggestion of a new study finding that older adults ...
Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to ...
A widely used, inexpensive gout drug could reduce heart attacks and strokes in people with cardiovascular disease, according to a new review. The work appears in the Cochrane Database of Systematic ...
Due to a policy decision in 2010 by the U.S. Food and Drug Administration (FDA), the price of a prescription for the therapeutic gout drug colchicine increased nearly 16-fold from $11.25 in 2009 to ...
BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke or high-risk TIA, according to the results of the CONVINCE trial. Through ...
Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price. Well intentioned, but costly and potentially problematic. That's how ...
(RTTNews) - Scilex Holding Co. (SCLX) announced that FDA has approved it request for the Orphan drug designation for colchicine for the treatment of pericarditis. Pericarditis is an inflammation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results